Skip to main content
. 2019 Sep 9;14(9):e0221863. doi: 10.1371/journal.pone.0221863

Table 10. Results obtained from the examination of UGV-2, S5-like and TSMV-2 specific S-segments by RT-PCR and UGV-1, UHV-1 NP and UHV-1 NP-C specific IgY and IgM antibodies by ELISA—Animals with BIBD.

RT-PCR UGV-1 UHV-1 NP UHV-1 NP-C
IgY IgM n = 33 tested IgY and IgM n = 33 tested IgY IgM IgY and IgM IgY IgM IgY and IgM
Positive
34/34 (100%)
Pos
9/34 (26.47%)
Pos
19/33 (57.58%)
Pos
7/33 (21.21%)
Pos 6/34 (17.65%) Pos 7/34 (20.59%) Pos
4/34 (11.76%)
Pos 7/34 (20.59%) Pos 10/34 (29.41%) Pos
5/34 (14.71%)
Neg 25/34 (73.53%) Neg
14/33 (42.42%)
Neg
13/33 (39.39%)
Neg 28/34 (82.35%) Neg 27/34 (79.41%) Neg
25/34 (73.53%)
Neg 27/34 (79.41%) Neg 24/34 (70.59%) Neg
22/34 (64.71%)
3 Segments 23/34 (67.65%) Pos
6/23 (26.09%)
Pos
14/22 (63.64%)
Pos
4/22 (18.18%)
Pos 2/23 (8.7%) Pos 4/23 (17.39%) Pos
1/23 (4.35%)
Pos 3/23 (13.04%) Pos 7/23 (30.43%) Pos
2/23
(8.7%)
Neg 17/23 (73.91%) Neg
8/22 (36.36%)
Neg
7/22 (31.82%)
Neg 21/23 (91.3%) Neg 19/23 (82.61%) Neg
18/23 (78.26%)
Neg 20/23 (86.96%) Neg 16/23 (69.57%) Neg
15/23 (65.22%)
2 Segments
9/34 (26.47%)
Pos
2/9 (22.22%)
Pos
3/9
(33.33%)
Pos
2/9
(22.22%)
Pos 3/9 (33.33%) Pos 2/9 (22.22%) Pos
2/9 (22.22%)
Pos 3/9 (33.33%) Pos 2/9 (22.22%) Pos
2/9 (22.22%)
Neg
7/9 (77.78%)
Neg
6/9
(66.67%)
Neg
6/9
(66.67%)
Neg 6/9 (66.67%) Neg 7/9 (77.78%) Neg
6/9 (66.67%)
Neg 6/9 (66.67%) Neg 7/9 (77.78%) Neg
6/9 (66.67%)
1 Segment
2/34 (5.88%)
Pos
1/2
(50%)
Pos
2/2
(100%)
Pos
1/2
(50%)
Pos
1/2
(50%)
Pos
1/2
(50%)
Pos
1/2
(50%)
Pos
1/2
(50%)
Pos
1/2
(50%)
Pos
1/2
(50%)
Neg
1/2
(50%)
Neg
0/2
(0%)
Neg
0/2
(0%)
Neg
1/2
(50%)
Neg
1/2
(50%)
Neg
1/2
(50%)
Neg
1/2
(50%)
Neg
1/2
(50%)
Neg
1/2
(50%)

Pos–positive; Neg—negative

HHS Vulnerability Disclosure